VEXAS Syndrome: Somatic UBA1 Mutations, Adult-Onset Hematologic-Rheumatologic Overlap, and Azacitidine to Transplant Therapy

VEXAS Syndrome: Somatic UBA1 Mutations, Adult-Onset Hematologic-Rheumatologic Overlap, and Azacitidine to Transplant Therapy

Adult-onset autoinflammatory disorder caused by somatic UBA1 mutations in myeloid precursors — recognized by macrocytic anemia plus systemic inflammation plus characteristic vacuoles in marrow myeloid precursors plus MDS-like clonal hematopoiesis.

Executive Summary

VEXAS (Vacuoles E1 enzyme X-linked Autoinflammatory Somatic) syndrome is an adult-onset systemic autoinflammatory disorder first described in 2020 by Beck and colleagues, caused by somatic mutations in UBA1 — the X-linked gene encoding the E1 ubiquitin-activating enzyme that initiates the ubiquitin-proteasome protein degradation pathway. The mutations occur exclusively in hematopoietic stem cells with downstream propagation through the myeloid lineage, producing a chimeric population of UBA1-mutated and wild-type cells. Because UBA1 is X-linked and somatic, the disorder predominantly affects men (typically over age 50) with a small minority of female cases reported in monosomy X / Turner syndrome contexts or with skewed X-inactivation. The clinical syndrome combines hematologic and rheumatologic features that historically would have been classified as separate diseases: chronic macrocytic anemia with elevated MCV often above 100 fL plus systemic inflammation manifesting as recurrent fevers, neutrophilic dermatoses (Sweet syndrome, neutrophilic urticaria), relapsing polychondritis features, pulmonary infiltrates, ocular inflammation (scleritis, uveitis), thromboembolism, and frequent overlap with myelodysplastic syndrome over time. The characteristic morphologic finding on bone marrow examination is vacuoles in myeloid precursors and erythroid precursors, present in approximately 80 percent of cases and providing the diagnostic clue when the clinical syndrome is recognized. Diagnosis rests on UBA1 sequencing demonstrating somatic mutation at methionine 41 (M41V, M41T, M41L being the most common) or at other locations, plus the characteristic clinical phenotype and marrow vacuolation. Treatment combines high-dose corticosteroids that produce dramatic clinical response in essentially all patients (but with substantial relapse on tapering), JAK inhibitors (ruxolitinib showing efficacy), IL-6 inhibitors (tocilizumab), hypomethylating agents (azacitidine targeting the clonal hematopoietic substrate), and allogeneic stem cell transplantation as the only curative option in fit patients. Mortality is substantial — approximately 50 percent at 5 years across published cohorts — and the disorder represents a major emerging entity in adult rheumatology and hematology requiring multidisciplinary management.
~1:13k
Estimated prevalence in men over 50
~95%
Male predominance (X-linked somatic mutation)
~50%
5-year mortality across published cohorts
~80%
Marrow myeloid vacuoles (diagnostic clue)

Contents

  1. Pathophysiology and Discovery
    • UBA1 somatic mutation biology
    • X-linked male predominance
    • Inflammatory cascade activation
  2. Diagnostic Evaluation
    • Clinical phenotype recognition
    • Marrow vacuoles morphology
    • UBA1 sequencing
  3. Treatment Strategies
    • Corticosteroid bridging
    • JAK inhibitors and biologic options
    • Azacitidine and stem cell transplantation
  4. Monitoring and Surveillance
  5. Clinical Commentary and Referral
  6. Practice Insights — Synthesized Patterns for VEXAS Care
  7. Frequently Asked Questions

S1. Pathophysiology and Discovery

VEXAS syndrome was identified in 2020 through unbiased genomic analysis of a cohort of adult men with treatment-refractory inflammatory disease that did not fit established autoimmune or autoinflammatory classifications. The investigators identified shared somatic mutations affecting methionine 41 (the catalytic residue near the active site) of UBA1, the X-linked gene encoding the ubiquitin-activating enzyme E1. UBA1 catalyzes the first step of the ubiquitin-proteasome pathway, activating ubiquitin in an ATP-dependent reaction that prepares the small protein for conjugation to substrates destined for proteasomal degradation. Loss of catalytic UBA1 activity disrupts the ubiquitin-proteasome system in mutated hematopoietic cells, producing accumulation of misfolded and ubiquitin-target proteins, endoplasmic reticulum stress, unfolded protein response activation, and downstream inflammatory cascade triggering through NF-κB and other pathways.

VEXAS: UBA1 somatic mutation, clinical phenotype, marrow vacuoles, treatment escalation Four-panel diagram covering UBA1 ubiquitin pathway, multi-organ inflammatory phenotype, marrow vacuoles in myeloid precursors, and treatment ladder from steroids to transplant. ① UBA1 Ubiquitin Pathway Defect Somatic UBA1 mutation in HSC → myeloid clone with E1 dysfunction Normal: UBA1 → E2 → E3 → Ub-protein → proteasome VEXAS (M41 mutation): UBA1⊗ → X (catalytically impaired) Consequences in mutated myeloid clone: • Failed ubiquitination → protein aggregation • Unfolded protein response activation • ER stress → NF-κB inflammation • Cytokine storm: IL-6, IFN, TNF X-linkage explains male predominance: • UBA1 on X chromosome • Males hemizygous → single mutation manifests • Females need biallelic / skewed X-inactivation ② Multi-Organ Inflammatory Phenotype Crosses hematologic and rheumatologic boundaries Hematologic • Macrocytic anemia (MCV often > 100 fL) • MDS-like clonal hematopoiesis • Thrombocytopenia, lymphopenia • Venous thromboembolism (~30-40%) Rheumatologic • Recurrent fevers (systemic inflammation) • Neutrophilic dermatoses (Sweet, neutrophilic urticaria) • Relapsing polychondritis features • Arthritis, vasculitis Other organ involvement • Pulmonary infiltrates, ground glass • Ocular (scleritis, uveitis) • Orchitis, epididymitis ③ Marrow Vacuoles — Diagnostic Clue Cytoplasmic vacuoles in myeloid and erythroid precursors (~80%) Promyelocyte with vacuoles: ↑ vacuoles Erythroblast with vacuoles: Vacuoles also seen in: • Copper deficiency • Chronic alcohol use • Some myelodysplastic syndromes Specificity comes from clinical context + UBA1 sequencing ④ Treatment Ladder Bridging / acute • Prednisone 0.5–1 mg/kg/day • Dramatic response in essentially all patients • High relapse on taper → chronic steroid dependence Steroid-sparing biologic • Ruxolitinib (JAK inhibitor) — emerging first-line • Tocilizumab (IL-6 inhibitor) • Anakinra (IL-1 receptor antagonist) Clone-directed (MDS overlap) • Azacitidine 75 mg/m² SC daily × 7 days q28 days • Targets clonal hematopoietic substrate • Combined with anti-inflammatory therapy Curative • Allogeneic SCT in fit patients • ~50% TRM in older multimorbid patients limits use

UBA1 is located on the X chromosome and the somatic mutations producing VEXAS occur in hematopoietic stem cells with downstream propagation through the myeloid lineage. The X-linked location of UBA1 explains the striking male predominance of the disorder: men are hemizygous for the X chromosome, so a single mutated UBA1 allele in a hematopoietic stem cell produces a clonal population of UBA1-deficient myeloid cells with no wild-type counterpart in those cells. Women have two X chromosomes and typically retain wild-type UBA1 activity on the non-mutated allele in mutated cells, requiring biallelic involvement or skewed X-inactivation to produce a similar phenotype. The reported female VEXAS cases generally involve monosomy X (Turner syndrome) or extremely skewed X-inactivation that effectively eliminates wild-type UBA1 expression in hematopoietic cells.

The mutations are clustered at methionine 41 (M41V, M41T, M41L as the most common variants accounting for over 90 percent of cases in published cohorts), with other UBA1 mutations producing similar phenotypes. The methionine 41 residue is part of a translation initiation site, and mutations at this position eliminate translation of the predominant cytoplasmic UBA1 isoform while preserving a less abundant nuclear isoform, producing a profound cytoplasmic UBA1 deficiency that disrupts the ubiquitin-proteasome system in myeloid cells. The downstream consequences include accumulation of unfolded proteins triggering endoplasmic reticulum stress, activation of the unfolded protein response, and downstream inflammatory cascade through NF-κB activation, type I interferon signaling, and cytokine storm including IL-6, TNF, and interferons. The clinical phenotype reflects this multi-pathway inflammatory activation. VEXAS UBA1 M41 Mutation Inflammatory CascadeVertical mechanistic cascade: hematopoietic stem cell acquires somatic UBA1 M41 mutation, loses the cytoplasmic UBA1b isoform while sparing nuclear UBA1a, disrupting ubiquitin-proteasome function; this drives ER stress and the unfolded protein response, NF-kB and type I interferon signaling, an IL-6 TNF interferon cytokine storm, and finally multi-organ autoinflammation with clonal myeloid expansion.VEXAS: From UBA1 M41 Mutation to Multi-Organ AutoinflammationSomatic UBA1 mutation in hematopoietic stem cellX-linked gene; hemizygous males → single hit manifestsMethionine 41 initiation-site mutationLoss of cytoplasmic UBA1b; nuclear UBA1a sparedM41V / M41T / M41L account for >90% of casesCytoplasmic ubiquitin-proteasome failureImpaired E1 ubiquitin activation → protein aggregationER stress & unfolded protein responseMisfolded protein accumulation in myeloid cloneNF-κB activation & type I interferon signalingInnate immune pathway ignitionCytokine storm: IL-6, TNF, interferonsTargets for JAK, IL-6 and IL-1 directed therapyMulti-organ autoinflammation + clonal myeloid expansionRheumatologic + hematologic (MDS) overlap phenotypeWhy males predominate (~95%)UBA1 sits on the X chromosomeHemizygous male: 1 mutant allele, nowild-type UBA1 in the clonal cellsRare females: monosomy X (Turner)or extreme skewed X-inactivationDownstream clinical read-outMacrocytic anemia (MCV > 100 fL)Recurrent fevers, marked CRP riseRelapsing polychondritis featuresSweet syndrome / neutrophilic urticariaPulmonary infiltrates, scleritis/uveitisVenous thromboembolism (~30-40%)MDS overlap, progression to AML

S2. Diagnostic Evaluation

The diagnostic workflow combines clinical phenotype recognition (the cross-disciplinary hematologic and rheumatologic features in an older man), morphologic confirmation through bone marrow examination showing the characteristic vacuoles, and molecular confirmation by UBA1 sequencing. Recognition is increasing as awareness of the disorder has grown since its 2020 description, but many cases are still being identified retrospectively in patients with longstanding refractory inflammatory disease previously classified as relapsing polychondritis, Sweet syndrome, polyarteritis nodosa, or MDS with autoimmune features.

TestVEXAS findingPractice pearl
Clinical phenotypeAdult-onset (typically male over 50) refractory inflammation + macrocytic anemia + multi-organ involvementDiagnostic suspicion most important when fitting historically distinct diagnoses don’t fully explain syndrome
CBC with MCVMacrocytic anemia (MCV typically > 100 fL); thrombocytopenia; lymphopenia in subsetMacrocytic anemia in setting of inflammation is the hematologic anchor
Inflammatory markersMarkedly elevated CRP (often > 100 mg/L); ESR elevatedPersistent elevation in patient with diverse organ involvement
FerritinOften elevated (acute phase plus possible iron overload)Helps gauge inflammatory burden
Bone marrow aspirate + biopsyVacuoles in myeloid precursors (promyelocytes) and erythroid precursors in ~80% of casesDiagnostic clue when present; sensitivity is imperfect but specificity good with clinical context
Marrow cytogeneticsFrequently normal; clonal abnormalities in MDS-overlap casesDocuments MDS evolution when present
UBA1 sequencingSomatic mutation at methionine 41 (M41V/M41T/M41L most common) or other locationsDefinitive diagnostic test; targeted sequencing from peripheral blood or marrow
Skin biopsy of involved lesionsNeutrophilic dermatosis (Sweet syndrome pattern) or other inflammatory infiltrateHistologic confirmation of skin manifestations
Imaging (chest CT)Pulmonary infiltrates, ground-glass opacities, alveolar hemorrhageSurveys pulmonary involvement
Vascular imaging (CT/MR angiography)Vasculitis features in subset; VTE evaluationPursue with clinical evidence of vascular involvement
ANA, ANCA, RF, anti-CCPNegative or non-specific; supports VEXAS rather than classical autoimmune diseaseNegative serology in face of clear inflammation supports VEXAS workup
Tryptase, complement, immunoglobulinsRoutine connective tissue / autoinflammatory workupExcludes alternative diagnoses

The clinical features that should specifically trigger VEXAS workup include: adult-onset (typically over 50) refractory inflammatory disease in a man; macrocytic anemia with MCV above 100 fL; coexisting features that historically span multiple specialty boundaries (rheumatologic-hematologic-dermatologic); poor response to or relapse on tapering of corticosteroids; relapsing polychondritis features with marked inflammatory markers; Sweet syndrome with systemic features; medium-vessel vasculitis with cytopenia; treatment-refractory MDS with inflammatory features; and recurrent venous thromboembolism with inflammation. The clinical pattern essentially crosses the historic specialty borders, and the diagnostic suspicion grows when no single classical diagnosis explains the entire syndrome. VEXAS Diagnostic Triad and UBA1 Variant ProfileThe three converging pillars required to diagnose VEXAS: recognizing the cross-disciplinary clinical phenotype in men over 50, finding cytoplasmic vacuoles in marrow myeloid and erythroid precursors in about 80 percent of cases, and confirming a somatic UBA1 mutation. Accompanying bars show the relative frequency of M41V, M41T and M41L variants and the typical 30 to 80 percent variant allele frequency reflecting clonal expansion.Diagnostic Triad & UBA1 Variant ProfileAll three pillars converge; UBA1 sequencing is the definitive test1Clinical phenotypeAdult-onset, male > 50Refractory inflammation +macrocytic anemiaCrosses rheum-heme-derm specialty bordersSteroid-dependent relapse2Marrow vacuolesCytoplasmic vacuoles in myeloid& erythroid precursors ≈ 80%3UBA1 sequencingDefinitive test; blood ormarrow DNASomatic mutation atmethionine 41Sanger or NGS myeloidpanel including UBA1Vacuoles are non-specific (copper deficiency, alcohol) — specificity comes from UBA1 confirmationM41 variant frequency (>90% of cases)M41Vmost commonM41TcommonM41LcommonOther<10% (non-M41)M41 lies in a translation initiation site → loss ofcytoplasmic UBA1 isoformVariant allele frequency (clonal burden)Typical range 30-80% in myeloid lineage0%30%80%100%<10%clonal expansionVAF < 10% suggests evolving diseaseor sampling variabilitySupporting labs: CRP often > 100 mg/L,ferritin elevated, ANA/ANCA negativeNegative serology supports VEXAS over classic autoimmunity

UBA1 sequencing is the definitive diagnostic test, performed from peripheral blood or bone marrow DNA. Targeted Sanger sequencing of the relevant exons or broader next-generation sequencing of myeloid panels including UBA1 can identify the somatic mutations. The variant allele frequency (VAF) of the UBA1 mutation typically ranges from 30 to 80 percent in the myeloid lineage, reflecting the clonal expansion of mutated cells. VAF below 10 percent in peripheral blood may suggest evolving disease or sampling variability. Bone marrow examination demonstrating the characteristic vacuoles in myeloid and erythroid precursors provides the morphologic diagnostic clue that can prompt sequencing when the clinical syndrome is recognized; however, the vacuoles can also be seen in copper deficiency and chronic alcohol use, with specificity coming from the clinical context plus UBA1 mutation confirmation.

Diagnostic pearl. Adult-onset (typically male over 50) refractory inflammatory disease combining hematologic (macrocytic anemia, MDS features) and rheumatologic (relapsing polychondritis, neutrophilic dermatosis, vasculitis) features that span historic specialty boundaries should prompt UBA1 sequencing for VEXAS syndrome. The diagnosis is increasingly recognized in patients with refractory disease previously labeled by component diagnoses; identifying the underlying VEXAS reframes management toward targeted clonal therapy rather than empirical immunosuppression alone.

S3. Treatment Strategies

Treatment in VEXAS is complex because the disorder bridges autoinflammatory disease (responsive to immunosuppression) and clonal hematopoietic disease (responsive to MDS-directed therapy or transplantation). Corticosteroids produce dramatic clinical response in essentially all patients but with substantial relapse on tapering, leading to chronic steroid dependence and complications. Steroid-sparing strategies include JAK inhibitors (ruxolitinib showing the most efficacy across published case series), IL-6 inhibitors (tocilizumab), and IL-1 inhibitors (anakinra). Clone-directed therapy with hypomethylating agents (azacitidine) targets the underlying clonal substrate. Allogeneic stem cell transplantation is the only curative option but carries substantial transplant-related mortality in the typically older multimorbid VEXAS population. VEXAS Treatment Ladder and Key Outcome RatesA four-rung escalation ladder for VEXAS therapy: high-dose prednisone bridging with universal but relapse-prone response, steroid-sparing biologics led by ruxolitinib, clone-directed azacitidine for MDS overlap, and curative allogeneic stem cell transplant limited by transplant-related mortality. A companion bar chart displays corticosteroid response near 100 percent, marrow vacuole rate 80 percent, lifetime venous thromboembolism risk 30 to 40 percent, transplant-related mortality 20 to 50 percent, and five-year mortality around 50 percent.Treatment Escalation Ladder & Key OutcomesEscalate as steroid dependence or MDS overlap emergesRung 1 · Bridging / acutePrednisone 0.5-1 mg/kg/day; near-universal response, relapse on taperRung 2 · Steroid-sparing biologicRuxolitinib 5-20 mg BID; alt tocilizumab, anakinraRung 3 · Clone-directed (MDS overlap)Azacitidine 75 mg/m² SC daily ×7d q28dRung 4 · CurativeAllogeneic SCT, reduced-intensity in fit patientsKey outcome & risk ratesCorticosteroid response~100%Marrow vacuoles present~80%Lifetime VTE risk30-40%Transplant-related mortality20-50%5-year mortality~50%Supportive care throughout• TMP-SMX 80/400 mg PO daily (PJP)• Anticoagulation for VTE (DOAC/warfarin)• Transfusion support; vaccinations• Distinguish drug cytopenia vs VEXAS

TherapyIndicationDoseNotes
PrednisoneBridging therapy and chronic maintenance0.5–1 mg/kg/day PO with prolonged taperDramatic clinical response; high relapse on taper
Methylprednisolone IV pulseSevere acute flares250–1000 mg IV daily × 3 daysBridge to oral; reserved for severe presentation
Ruxolitinib (JAK inhibitor)Steroid-sparing; emerging first-line steroid-sparing option5–20 mg PO BID titratedCase series support; targets cytokine signaling driving inflammation
TocilizumabRefractory inflammation; IL-6 dominant phenotype162 mg SC weekly or 8 mg/kg IV monthlyIL-6 receptor antagonist; case series support
AnakinraIL-1 inhibition for refractory inflammation100 mg SC dailyShort half-life; less established than JAK or IL-6 inhibition
AzacitidineMDS overlap; clone-directed therapy75 mg/m² SC daily × 7 days q28 daysTargets clonal hematopoietic substrate; modest response on inflammation
Allogeneic stem cell transplantationFit patients; curative intentPer transplant protocol with reduced-intensity conditioningOnly curative option; TRM 20–50% in older multimorbid population
MethotrexateSteroid-sparing with chronic inflammation15–25 mg PO/SC weekly + folateModest response; less effective than JAK or IL-6 inhibitor monotherapy
Cyclosporine, mycophenolateAlternative steroid-sparingPer protocolCase-by-case based on dominant features
AnticoagulationVTE (~30–40% lifetime risk)DOAC or warfarin per standard VTE protocolStrongly consider primary prophylaxis given high VTE risk
Transfusion supportSymptomatic anemia or thrombocytopeniaPer threshold and symptomsChronic transfusion in advanced disease
Pneumocystis prophylaxisChronic steroid plus immunosuppressionTMP-SMX 80/400 mg PO dailyEssential during sustained immunosuppression
VaccinationsInfluenza pneumococcal zoster COVIDAnnual flu; pneumococcal per scheduleUpdate before transplant or biologic initiation

Corticosteroids remain the cornerstone of acute management because of the dramatic response — essentially all VEXAS patients respond to prednisone at 0.5–1 mg/kg/day with rapid reduction of inflammatory symptoms, fever resolution, and inflammatory marker decline. The challenge is sustained maintenance because steroid tapering below approximately 15–20 mg daily typically produces relapse. Established practice combines prednisone with steroid-sparing biologic therapy (ruxolitinib, tocilizumab, anakinra) to permit lower steroid doses and reduce long-term steroid morbidity. Ruxolitinib has emerged as the most promising steroid-sparing option based on case series demonstrating efficacy across the inflammatory spectrum, with dosing typically 5–20 mg twice daily titrated to clinical response and tolerability.

Clone-directed therapy with hypomethylating agents addresses the underlying clonal hematopoietic substrate. Azacitidine 75 mg/m² subcutaneous daily for 7 days every 28 days is the standard MDS regimen and has been used in VEXAS with MDS overlap and progressive cytopenias, producing modest inflammatory response in addition to hematologic improvement. The therapy is typically combined with anti-inflammatory regimens rather than used as monotherapy. Allogeneic stem cell transplantation is the only currently curative therapy, targeting both the inflammatory and clonal hematologic components by replacing the entire UBA1-mutated hematopoietic system with donor-derived wild-type cells. Transplant-related mortality (20–50 percent) is substantial in the typically older multimorbid VEXAS population, limiting the procedure to younger and fitter candidates. Reduced-intensity conditioning regimens improve tolerability in selected older patients.

When to refer. Multidisciplinary involvement is essential — rheumatology consultation for inflammatory phenotype management, hematology for marrow evaluation and clone-directed therapy planning, dermatology for skin lesion management, and transplant consultation when stem cell transplant is being considered. Specialized VEXAS clinics or autoinflammatory disease centers at academic medical centers offer the best outcomes for complex multi-organ disease. Genetic counseling addresses the somatic (not germline) nature of the mutations and the absence of inheritance risk to offspring.

S4. Monitoring and Surveillance

Monitoring centers on inflammatory disease activity, steroid taper management, hematologic surveillance for MDS evolution and progression, infection surveillance during immunosuppression, and complication management (VTE, infections, steroid-related morbidity). The chronic relapsing course with high relapse rate on steroid tapering requires ongoing care at 1–3 month intervals indefinitely.

Phase / DomainWhat to monitorFrequency
Active diseaseSymptom assessment CBC CRP ESR ferritinEvery 2–4 weeks
Steroid taper phaseSymptom recurrence CBC inflammatory markers glucose BPMonthly during taper
Stable maintenanceCBC inflammatory markers symptom diaryEvery 1–3 months
Marrow surveillanceRepeat bone marrow with cytogenetics MDS evolution assessmentAnnually or with cytopenia progression
UBA1 VAF trackingTrends in clonal burdenEvery 6–12 months (selective)
VTE surveillance and prophylaxisSymptom assessment risk reassessmentEvery visit; primary prophylaxis consideration
Infection surveillancePJP prophylaxis vaccination status fungal/viral risk during immunosuppressionEvery visit
Steroid-related complicationsBone density glucose lipids BP weightAnnual DXA; routine labs
Cardiovascular surveillanceBP lipids cardiovascular event monitoringPer standard cardiovascular risk management

MDS progression is the long-term hematologic concern. A meaningful fraction of VEXAS patients develop frank myelodysplastic syndrome over follow-up with progressive cytopenias and increased marrow blast percentages. Some progress to acute myeloid leukemia. Surveillance bone marrow examination with cytogenetics and next-generation sequencing of myeloid mutation panels at annual intervals or with significant cytopenia progression identifies MDS evolution and triggers hypomethylating agent therapy or transplant evaluation. VTE risk (approximately 30–40 percent lifetime) is substantial and may justify primary prophylaxis with low-dose anticoagulation in selected patients, with established practice considering this in patients with severe inflammation, prior VTE, or other prothrombotic risk factors.

S5. Clinical Commentary and Referral

VEXAS syndrome is the prototype of a new class of adult-onset autoinflammatory disorders driven by somatic mutations in hematopoietic stem cells. The disorder fundamentally crosses the historic boundaries of rheumatology and hematology and represents the diagnostic challenge of an entity that didn’t have a name until 2020 but explains a meaningful fraction of previously refractory adult inflammatory disease. Established practice has rapidly incorporated UBA1 sequencing into the workup of refractory adult inflammatory disease in men over 50, particularly when hematologic features (macrocytic anemia, MDS features) accompany the rheumatologic presentation.

Pearl. Adult-onset (typically male over 50) refractory inflammatory disease combining hematologic features (macrocytic anemia with MCV above 100 fL, MDS features) and rheumatologic features (relapsing polychondritis, Sweet syndrome, vasculitis) should prompt UBA1 sequencing for VEXAS syndrome. The disorder is increasingly recognized in patients with refractory disease previously classified by their dominant component diagnoses. Identifying the underlying VEXAS reframes management toward targeted clonal therapy and stem cell transplantation rather than empirical immunosuppression alone.
Pitfall. Treating VEXAS patients with prolonged high-dose corticosteroid monotherapy without considering steroid-sparing biologic therapy or clone-directed therapy produces cumulative steroid morbidity (osteoporosis diabetes cardiovascular disease infections) without addressing the underlying clonal substrate. Established practice combines prednisone with steroid-sparing agents (ruxolitinib tocilizumab anakinra) and considers azacitidine or stem cell transplantation in eligible patients.
Refer urgently to rheumatology and hematology jointly for any adult-onset refractory inflammatory disease combining hematologic and rheumatologic features for VEXAS workup, any patient with characteristic marrow vacuoles for UBA1 sequencing, any UBA1-positive patient for treatment planning, any patient with VEXAS plus MDS evolution for hypomethylating agent consideration, and any fit younger VEXAS patient for stem cell transplant evaluation. Specialized VEXAS or autoinflammatory disease centers at academic medical centers offer optimal multidisciplinary care.

S6. Practice Insights — Synthesized Patterns for VEXAS Care

(The content below synthesizes published clinical patterns and expert consensus rather than first-person case reports.) Across published VEXAS cohorts and emerging registries, experienced practice has converged on a recognizable algorithm: cross-disciplinary inflammatory disease in older men warrants UBA1 sequencing; macrocytic anemia plus marrow vacuoles plus inflammation is the diagnostic triad; corticosteroid response is universal but tapering produces relapse; ruxolitinib has emerged as a leading steroid-sparing option; and allogeneic stem cell transplantation is the only curative therapy with substantial risks.

What the Guideline Misses

Experienced clinicians have learned that VEXAS is consistently missed when refractory inflammatory disease in older men is diagnosed by its dominant component (relapsing polychondritis Sweet syndrome polyarteritis nodosa) without consideration of the unifying underlying disorder. Established practice considers VEXAS in any treatment-refractory adult inflammatory disease in men over 50 particularly when macrocytic anemia accompanies the inflammatory features.

Patterns That Repeat

Across published case series the cross-specialty boundary nature of VEXAS results in fragmented care when hematology and rheumatology manage component features in isolation. Established practice integrates care through joint clinic models or multidisciplinary VEXAS conferences that coordinate corticosteroid management steroid-sparing biologic decisions clone-directed therapy considerations and transplant evaluation across specialties.

The Bedside Heuristic

Established practice has increasingly adopted ruxolitinib as first-line steroid-sparing therapy in VEXAS based on case series demonstrating efficacy across the inflammatory spectrum. The JAK inhibition targets the cytokine signaling driving the multi-organ inflammation and allows substantial steroid dose reduction in many patients. Tocilizumab and anakinra remain alternatives particularly when IL-6 or IL-1 dominance is suggested by phenotype.

Illustrative Scenario — Retrospectively Recognized VEXAS

A composite scenario from published series describes a man in his late 60s with 4 years of progressive refractory inflammatory disease previously managed under multiple component diagnoses. Initial presentation 4 years prior was relapsing polychondritis with ear cartilage inflammation and treatment response to prednisone followed by relapse on tapering. Two years prior, neutrophilic urticaria appeared with skin biopsy consistent with Sweet syndrome. Eighteen months prior, deep vein thrombosis prompted anticoagulation. Six months prior, progressive macrocytic anemia (Hb 9.4 g/dL, MCV 108 fL) and mild thrombocytopenia (platelets 110 × 10^9/L) prompted bone marrow examination which showed myelodysplastic syndrome with multilineage dysplasia and characteristic vacuoles in myeloid and erythroid precursors. UBA1 sequencing identifies a somatic M41V mutation with variant allele frequency 65 percent in peripheral blood. The diagnosis of VEXAS syndrome reframes the multi-year disease course as a unified entity. Treatment is reorganized: prednisone tapered slowly to 10 mg daily, ruxolitinib initiated at 10 mg twice daily, anticoagulation continued, pneumocystis prophylaxis added, azacitidine added for the MDS component. At 12 months on combination therapy the patient achieves substantial reduction in inflammatory activity and stable hematology with no major flares. Stem cell transplant evaluation is performed but deferred given comorbidity profile and patient preference.

What this synthesis teaches: VEXAS frequently presents as sequential or simultaneous component diagnoses (relapsing polychondritis Sweet syndrome MDS VTE) that span multiple specialty boundaries over years. Recognition of the unifying disorder reframes management toward combination immunosuppression with steroid-sparing biologic plus clone-directed therapy plus consideration of stem cell transplantation. The diagnosis is often made retrospectively when the cross-disciplinary pattern is recognized; established practice considers VEXAS earlier in refractory inflammatory disease workup.

Practice Pattern Refinements

  1. Order UBA1 sequencing in any adult-onset refractory inflammatory disease in men over 50 particularly when macrocytic anemia (MCV above 100 fL) coexists with the inflammatory features. Established practice integrates UBA1 testing into the workup of treatment-refractory relapsing polychondritis Sweet syndrome polyarteritis nodosa or other adult inflammatory disorders rather than waiting for retrospective recognition after years of fragmented component-diagnosis management.
  2. Examine bone marrow specifically for cytoplasmic vacuoles in myeloid and erythroid precursors when VEXAS is suspected. The vacuoles are present in approximately 80 percent of cases and provide a morphologic diagnostic clue that prompts UBA1 sequencing. The vacuoles are also seen in copper deficiency and chronic alcohol use so specificity depends on clinical context plus UBA1 mutation confirmation.
  3. Combine corticosteroids with steroid-sparing biologic from the outset rather than relying on prolonged steroid monotherapy. Ruxolitinib 5–20 mg twice daily titrated to clinical response has emerged as the leading steroid-sparing option based on case series. Tocilizumab and anakinra are alternatives. Combination therapy enables lower sustained prednisone doses and reduced long-term steroid morbidity while maintaining inflammatory control.
  4. Evaluate fit younger VEXAS patients for allogeneic stem cell transplantation as the only currently curative therapy. Transplant-related mortality is substantial (20–50 percent) in the typically older multimorbid population but is the only option offering cure of both the inflammatory and clonal hematologic components. Reduced-intensity conditioning regimens improve tolerability in selected older fit patients and expand transplant eligibility compared with full-intensity protocols.

S7. Frequently Asked Questions

What is VEXAS syndrome?
VEXAS (Vacuoles E1 enzyme X-linked Autoinflammatory Somatic) syndrome is an adult-onset systemic autoinflammatory disorder first described in 2020 caused by somatic mutations in UBA1 — the X-linked gene encoding the E1 ubiquitin-activating enzyme. The mutations occur in hematopoietic stem cells with downstream propagation through the myeloid lineage, producing chronic inflammation, macrocytic anemia, and frequent overlap with myelodysplastic syndrome. The disorder predominantly affects men over 50 because UBA1 is X-linked and the somatic mutations produce manifest disease in hemizygous males. The clinical syndrome combines rheumatologic features (relapsing polychondritis Sweet syndrome vasculitis) and hematologic features (macrocytic anemia MDS) that historically would have been classified as separate diseases.
Why is VEXAS predominantly in men?
UBA1 is located on the X chromosome. Men are hemizygous for the X chromosome — they have only one X chromosome — so a single somatic UBA1 mutation in a hematopoietic stem cell produces a clonal population of cells with no wild-type UBA1 counterpart in those mutated cells. Women have two X chromosomes and typically retain wild-type UBA1 activity on the non-mutated allele in mutated cells through normal X-inactivation patterns. The reported rare female VEXAS cases generally involve monosomy X (Turner syndrome) or extremely skewed X-inactivation that effectively eliminates wild-type UBA1 expression in the hematopoietic clone. The X-linked location combined with the somatic origin produces the striking male predominance approaching 95 percent in published cohorts.
How is VEXAS diagnosed?
Diagnosis combines clinical phenotype recognition (cross-disciplinary hematologic and rheumatologic features in adult-onset usually male over 50) with morphologic confirmation (bone marrow showing characteristic cytoplasmic vacuoles in myeloid and erythroid precursors in approximately 80 percent of cases) and molecular confirmation (UBA1 somatic mutation typically at methionine 41 — M41V M41T or M41L being most common). UBA1 sequencing from peripheral blood or bone marrow DNA is the definitive test. Variant allele frequency typically ranges from 30 to 80 percent reflecting clonal expansion in the myeloid lineage.
What is the role of ruxolitinib?
Ruxolitinib is a JAK1/JAK2 inhibitor that has emerged as the leading steroid-sparing therapy in VEXAS based on case series demonstrating efficacy across the inflammatory spectrum. The drug targets cytokine signaling through the JAK-STAT pathway driving the multi-organ inflammation of VEXAS. Dosing typically begins at 5 mg twice daily with titration to 10–20 mg twice daily based on clinical response and tolerability. Side effects include cytopenia (which must be distinguished from VEXAS-related cytopenia) infection risk (particularly herpes zoster) and dose-related effects. Tocilizumab (IL-6 inhibitor) and anakinra (IL-1 receptor antagonist) are alternative steroid-sparing biologic options.
What is the prognosis?
Long-term outcomes are challenging in VEXAS — approximately 50 percent 5-year mortality across published cohorts reflects the combined burden of multi-organ inflammation cytopenia infection complications and progression to overt MDS or AML. Median age at diagnosis approaching 70 years and substantial comorbidity contribute to the mortality profile. Outcomes are improving as awareness grows and treatment approaches evolve with steroid-sparing biologic therapy clone-directed therapy and stem cell transplantation. Younger fit patients who undergo successful allogeneic stem cell transplantation can achieve disease cure with normalization of inflammatory and hematologic features. The disorder represents a major unmet need in adult inflammatory disease management and is the subject of intensive research.
Is stem cell transplantation curative?
Yes — allogeneic stem cell transplantation is the only currently curative therapy for VEXAS by replacing the entire UBA1-mutated hematopoietic system with donor-derived wild-type cells. Transplant-related mortality (20–50 percent) is substantial in the typically older multimorbid VEXAS population limiting the procedure to younger and fitter candidates. Reduced-intensity conditioning regimens improve tolerability in selected older fit patients and have expanded transplant eligibility compared with full-intensity myeloablative protocols. Long-term outcomes in successfully transplanted patients are excellent with normalization of inflammatory features hematologic recovery and elimination of the UBA1-mutated clone. Transplant evaluation is established practice for fit younger VEXAS patients.
Can VEXAS be inherited?
No — VEXAS results from somatic (not germline) mutations in hematopoietic stem cells acquired during adult life. The mutations are not present in germ cells (sperm or eggs) and therefore cannot be transmitted to offspring. Family screening is unnecessary unlike inherited disorders. Established practice provides genetic counseling clarifying the somatic nature of the mutations and reassuring patients about the absence of inheritance risk. The somatic origin distinguishes VEXAS from classical hereditary autoinflammatory disorders (familial Mediterranean fever cryopyrin-associated periodic syndromes etc) where germline mutations produce inheritable disease.

Leave a Reply

Your email address will not be published. Required fields are marked *